Trial · NCT04390646
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cognition | Baseline to end of treatment (Week 24) | Montreal Cognitive Assessment (MoCA) total score ranges between 0 and 30 (cut-off set at 26 for the healthy population) Higher scores reflect better performance. |
| Secondary | Dimensional change card sorting task (DCCS) | baseline to end of treatment (Week 24) | change in score of DCCS to assess executive functions |
| Secondary | Paired Associated Learning (PAL, part of the CANTAB battery) | baseline to end of treatment (Week 24) | change in score of PAL to assess learning |
| Secondary | Token test | baseline to end of treatment (Week 24) | change in score of Token test to assess verbal comprehension |
| Secondary | Corsi block tapping task | baseline to end of treatment (Week 24) | change in score to assess visuospatial memory |
| Secondary | Litmus non-word-repetition test | baseline to end of treatment (Week 24) | change in score of Litmus test to assess phonological abilities |
| Secondary | Health-related quality of life SF-12 | baseline to end of treatment (Week 24) | The health-related quality of life (HRQoL) can be used to measure the effects of healthcare interventions and provide quality-improvement outcomes. The Short Form-12 (SF-12) Health Survey is widely used in measuring HRQoL. SF-12 is a reliable, valid measure in a variety of population groups; it is an equivalent substitute for the SF-36v2 for the summary scales. The response to each of the 12 items is weighted separately by the physical and mental component summary (PCS and MCS) regression coefficients and then calculated to give the SF-12 PCS and MCS scores. |
| Secondary | Adaptive behavior (Vineland II) - caregiver questionnaire | baseline to end of treatment (Week 24) | change in score of Vineland II (normed assessment tool that assesses adaptive behavior across the areas of communication, activities of daily living, and socialization). |
| Secondary | Glycemia | baseline to end of treatment (Week 24) | Glucose concentration (mmol/L) is a metabolic parameter. |
| Secondary | Insulinemia | baseline to end of treatment (Week 24) | Insulin concentration (nmol/L) is a metabolic parameter. |
| Secondary | Total cholesterol | baseline to end of treatment (Week 24) | Total cholesterol (mmol/L) is a metabolic parameter. |
| Secondary | High density lipoprotein (HDL)-cholesterol | baseline to end of treatment (Week 24) | HDL-cholesterol (mmol/L) is a metabolic parameter. |
| Secondary | Low density lipoprotein (LDL)-cholesterol | baseline to end of treatment (Week 24) | LDL-cholesterol (mmol/L) is a metabolic parameter. |
| Secondary | Triglycerides | baseline to end of treatment (Week 24) | Triglycerides (mmol/L) is a metabolic parameter. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04390646/registered